H McFarland
Overview
Explore the profile of H McFarland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suto D, Nair G, Sudarshana D, Steele S, Dwyer J, Beck E, et al.
AJNR Am J Neuroradiol
. 2020 Aug;
41(9):1569-1576.
PMID: 32763897
Background And Purpose: Cellular uptake of the manganese ion, when administered as a contrast agent for MR imaging, can noninvasively highlight cellular activity and disease processes in both animals and...
2.
Bielekova B, Richert N, Herman M, Ohayon J, Waldmann T, McFarland H, et al.
Neurology
. 2011 Nov;
77(21):1877-86.
PMID: 22076546
Objectives: We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that...
3.
Ravina B, Eidelberg D, Ahlskog J, Albin R, Brooks D, Carbon M, et al.
Neurology
. 2005 Jan;
64(2):208-15.
PMID: 15668415
Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the...
4.
Kappos L, Weinshenker B, Pozzilli C, Thompson A, Dahlke F, Beckmann K, et al.
Neurology
. 2004 Nov;
63(10):1779-87.
PMID: 15557490
Background: A European (EU) and a North American (NA) placebo-controlled study with interferon beta-1b (IFNB-1b) in secondary progressive multiple sclerosis (SPMS) showed divergent results with regard to their primary outcome...
5.
Leigh R, Ostuni J, Pham D, Goldszal A, Lewis B, Howard T, et al.
Mult Scler
. 2002 Oct;
8(5):420-9.
PMID: 12356210
Purpose: The purpose of this study was to determine how measures reflecting cerebral atrophy (CA) are influenced by pulse sequence (PS) and segmentation algorithm (SA) used in multiple sclerosis (MS)...
6.
Frank J, Richert N, Lewis B, Bash C, Howard T, Civil R, et al.
Mult Scler
. 2002 Apr;
8(1):24-9.
PMID: 11936485
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease...
7.
Burt R, Brenner M, Burns W, Courier E, Firestein G, Hahn B, et al.
J Clin Immunol
. 2000 May;
20(1):1-9.
PMID: 10798601
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our...
8.
Bagnato F, Tancredi A, Richert N, Gasperini C, Bastianello S, Bash C, et al.
Mult Scler
. 2000 Mar;
6(1):43-9.
PMID: 10694845
Magnetic resonance imaging (MRI) has been used to study the history of multiple sclerosis (MS). We analyze the relationship between MRI activity in the first scan compared to the subsequent...
9.
Bielekova B, Lincoln A, McFarland H, Martin R
J Immunol
. 2000 Jan;
164(2):1117-24.
PMID: 10623864
Phosphodiesterase-4 (PDE4) inhibitors have the potential to modulate immune responses from the Th1 toward the Th2 phenotype and are considered candidate therapies for Th1-mediated autoimmune disorders. However, depending on the...
10.
Roca C, Su T, ELPERN S, McFarland H, Rubinow D
Biol Psychiatry
. 1999 Aug;
46(4):551-6.
PMID: 10459406
Background: Cerebrospinal fluid (CSF) somatostatin (SS) levels have been shown to be decreased in multiple sclerosis (MS) during relapse as well as in disorders characterized by depression or cognitive impairment....